



**Bristol-Myers Squibb Company**

655 15th Street, N.W., Suite 700 Washington, DC 20005 202 783-0900

SECRETARY OF THE SENATE

01 AUG -2 PM 4: 10

Richard L. Thompson  
Vice President  
Government Affairs

August 1, 2001

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Gentlemen:

As per your letter of July 11, 2001 (copy enclosed), I am forwarding to you an amended 2000 year-end Lobbying Report, adding on line 18, pages 4 & 8, the name of our employee who acted as a lobbyist for those issues. The name of that employee was inadvertently deleted after being listed on line 23 on the Information Update page in that same report.

As requested, a separate filing of the amended report is being made with the Secretary of the Senate.

If you have any questions, please do not hesitate to contact either John Ryan or myself at (202) 783-0900.

Sincerely,

Richard L. Thompson

Jeff Trandahl  
Clerk

H-154 The Capitol

Office of the Clerk  
U.S. House of Representatives  
Washington D.C. 20515-6601

SECRETARY OF THE SENATE  
01 AUG -2 PM 4:11

MR. RICHARD THOMPSON  
BRISTOL-MYERS SQUIBB CO  
655 15TH STREET, NW, #410  
WASHINGTON, DC 20005

July 11, 2001

ID: 31580000

The Lobbying Disclosure Act of 1995 (2 USC 1601) directs the Clerk of the House of Representatives to "review, and, where necessary, verify and inquire to ensure the accuracy, completeness and timeliness of registrations and reports".

A preliminary review of your 2000 Year-End Report filed with the Office of the Clerk indicates the following omissions and/or errors:

- \* Line 18 was omitted for pages 4 and 8. Please disclose the name of each employee who acted as a lobbyist during the reporting period; or, if no lobbyist performed lobbying activities during the reporting period, state "None".

Please file an amended Report Form correcting these omission(s) and/or error(s) within thirty days, with the Legislative Resource Center, B106 Cannon House Office Building, Washington, D.C. 20515. Line numbers referenced in this notice refer to forms LD-1 and LD-2 dated June, 1998.

If you have any questions regarding this matter, please do not hesitate to contact the Legislative Resource Center at (202) 226-5200.

*\* Please Note: The law requires a separate filing with the Secretary of the Senate.*

.01 AUG -2 PM 4: 10

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name <b>Bristol-Myers Squibb Company</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>655 15th St. NW</b> City <b>Washington DC</b> State/Zip (or Country) <b>20005 USA</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>Richard Thompson</b>	Telephone <b>(202) 783-0900</b>	E-mail (optional)	5. Senate ID # <b>7053-12</b>
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # <b>7053</b>

**TYPE OF REPORT** 8. Year 2000 Midyear (January 1-June 30)  OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  >> Termination Date \_\_\_\_\_ If. No Lobbying Activity

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p><b>12. Lobbying Firms</b></p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> &gt;&gt; \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p><b>13. Organizations</b></p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> &gt;&gt; \$ <u>\$2,220,000.00</u> Expenses (nearest \$20,000)</p> <p><b>14. REPORTING METHOD.</b> Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Richard Thompson Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 1 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues

**H.CON.RES.290, Resolved by the House of Representatives (the Senate concurring), Lobbied for funding for Medicare and Medicaid programs.**

**H.R.4461, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001, Lobbied to add safety features to prescription drug import provisions.**

**H.R.4577, The Consolidated Appropriations Act for FY 2001, Advocated for changes in Medicare payment rate for oncology and coverage criteria for ostomy products.**

**S.2536, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001, Lobbied to add safety features to prescription drug import provisions.**

**S.2553, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Lobbied to increase funding for Ryan White program.**

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Agriculture  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<b>Carozza, Michael</b>		No
<b>Keaney, David</b>		No
<b>Thompson, Richard</b>		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 2 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.CON.RES.101, Setting forth the congressional budget for the United States Government for fiscal years 2001 through 2005 and revising the budgetary levels for fiscal year 2000, Lobbied for funding for Medicare and Medicaid programs.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CAW (one per page)

16. Specific Lobbying issues

**EPA: Creation of Office of Information to ensure data quality and accessibility.**

17. House(s) of Congress and Federal agencies contacted  Check if None

**Environmental Protection Agency  
House of Representatives  
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<b>Skrabut, Lucy</b>		<b>No</b>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 4 of 22

Registrant Name: Bristol Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

- H.R.1225, United States Patent and Trademark Office Reauthorization Act, Fiscal Year 2000, Monitor the effect of the bill on the pharmaceutical industry.
- H.R.1598, Patent Fairness Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
- H.R.1907, American Inventors Protection Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
- H.R.769, Madrid Protocol Implementation Act, Monitor the effect of the bill on the pharmaceutical industry.
- S.1172, Drug Patent Term Restoration Review Procedure Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
- S.1258, Patent Fee Integrity and Innovation Protection Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
- S.1259, Trademark Amendments Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
- S.671, Madrid Protocol Implementation Act, Monitor the effect of the bill on the pharmaceutical industry.

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Commerce  
House of Representatives  
Senate  
USTR

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 5 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.804, Technology Transfer Commercialization Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
16	Lobbying Issues	S.999, Technology Transfer Act of 1999, Monitor the effect of the bill on the pharmaceutical industry.
16	Lobbying Issues	Hatch/Waxman Reform, protecting interests of innovator companies. Protection of Data Exclusivity Agreement, monitoring bills that might impact on Cooperative Research and Development Agreements (CRADA).

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues

H.R.1323, Silicone Breast Implant Research and Information Act, Supporting efforts to limit the ability to admit "junk science" in breast implant liability cases.

S.1075, Silicone Breast Implant Research and Information Act, Supporting efforts to limit the ability to admit "junk science" in breast implant liability cases.

17. House(s) of Congress and Federal agencies contacted

Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Ryan, John		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_ Date 8/1/2004

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 7 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)

16. Specific Lobbying issues  
H.R.1190, Solid Waste Interstate Transportation and Local Authority Act of 1999, Opposing RCRA reform.

17. House(s) of Congress and Federal agencies contacted  Check if None  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<u>Skrabut, Lucy</u>		<u>No</u>

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 8 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOR (one per page)

16. Specific Lobbying issues

**H.R.434, African Growth and Opportunity Act, Advocate position for the protection of intellectual property rights.  
S.1387, African Growth and Opportunity Act, Advocate position for the protection of intellectual property rights.  
S.2466, To require the United States Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs, Advocate for the elimination of foreign price controls.**

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Commerce  
Food & Drug Administration  
House of Representatives  
Senate  
U.S. Agency for International Development  
U.S. Department of State  
U.S. Trade Representative

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Thompson, Richard		No
Warr, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 9 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	<p>Belgium dioxin contamination. Lobbied to reverse ban on importation of certain products.</p> <p>Southern Africa AIDS Initiative: Assist South Africa, Botswana, Namibia, Lesotho and Swaziland to find solutions for women and children suffering from the HIV/AIDS epidemic.</p> <p>Biological Weapons Convention Enforcement Issues: Ensure that an equitable and reasonable compliance protocol is adopted.</p> <p>New Zealand Pricing Scheme: Lobbied to reverse pricing actions that would affect the reimbursement of certain pharmaceutical products in the country.</p>

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code GOV (one per page)

16. Specific Lobbying issues

H.R.1320, Millennium Digital Commerce Act, Advocate for adequate protections for industry interests.

H.R.1612, Consumer Food Safety Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.

H.R.1714, Electronic Signatures in Global and National Commerce Act, Advocate for adequate protections for industry interests.

H.R.2100, Antitampering Act of 1999, Advocate for the prohibition of unauthorized destruction of product identification codes.

H.R.4049, Privacy Commission Act, Advocate for the protection and use of information for medical research.

H.R.4109, Worker Economic Opportunity Act, Advocate for greater worker participation in stock option plans.

H.R.4180, Library of Congress Financial Management Act of 2000, Advocate for greater worker participation in stock option plans.

17. House(s) of Congress and Federal agencies contacted  Check if None

Department of Agriculture  
Department of Health and Human Services  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 11 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.4461, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001, Advocate for fair treatment in WIC program.
16	Lobbying Issues	H.R.4576, Department of Defense Appropriations Act, 2001, Advocate for the protection and use of information for medical research.
16	Lobbying Issues	H.R.4577, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Advocate increased funding for the NIH and fair treatment for pharmaceutical companies that enter into Cooperative Research Agreements and Development Agreements (CRADA's)
16	Lobbying Issues	H.R.4585, Medical Financial Privacy Protection Act, Advocate for adequate protections and use of information for medical research.
16	Lobbying Issues	H.R.836, Imported Food Safety Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.
16	Lobbying Issues	S.1123, Imported Food Safety Improvement Act, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.
16	Lobbying Issues	S.1126, Imported Food Safety Improvement Act of 1999, Monitor bill and advocate position that protect the company's products and the best interests of the consumer.
16	Lobbying Issues	S.2323, Worker Economic Opportunity Act, Advocate for greater worker participation in stock option plans.
16	Lobbying Issues	S.2536, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2001, Advocate for fair treatment in WIC program.
16	Lobbying Issues	S.2553, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2001, Advocate increased funding for the NIH and fair treatment for pharmaceutical companies that enter into Cooperative Research Agreements and Development Agreements (CRADA's)
16	Lobbying Issues	S.761, Millennium Digital Commerce Act, Advocate for adequate protections for industry interests.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY:** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

- H.R. 4577, The Consolidated Appropriations Act for FY 2001, Advocated for changes in Medicare payment rate for oncology and coverage criteria for oslomy products.
- H.R.1057, Medical Information Privacy and Security Act, Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.
- H.R.1109, Medicare Outpatient Prescription Drug Coverage Act of 1999, Lobbied on Medicare coverage regulations.
- H.R.1204, Environmental Equalization and Energy Security Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
- H.R.1388, Medicare Cancer Clinical Trial Coverage Act of 1999, Monitor the bill and advocate positions that promote medical research.
- H.R.1495, Access to Prescription Medications in Medicare Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.

17. House(s) of Congress and Federal agencies contacted  Check if None  
Health Care Finance Administration - HCFA  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Ryan, John		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 13 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.1596, Consumer Involvement in Breast Cancer Research Act, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	H.R.1796, Medicare Chronic Disease Prescription Drug Benefit Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.1885, International Prescription Drug Parity Act, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.2839, Medicare Patient Access to Technology Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.2457, Genetic Nondiscrimination in Health Insurance and Employment Act of 1999, Monitor the effect of the bill on medical research.
16	Lobbying Issues	H.R.2488, Taxpayer Refund and Relief Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.2782, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.2925, Medicare Beneficiary Prescription Drug Assistance and Stop-Loss Protection Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.2927, Affordable Prescription Drugs Act, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.293, Genetic Information Health Insurance Nondiscrimination Act of 1999, Monitor the effect of the bill on medical research.
16	Lobbying Issues	H.R.386, Genetic Information Nondiscrimination in Health Insurance Act of 1999, Monitor the effect of the bill on medical research.
16	Lobbying Issues	H.R.3875, Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	H.R.3194, Making consolidated appropriations for the fiscal year ending September 30, 2000, and for other purposes, Lobbied to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	H.R.3240, Drug Import Fairness Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.3426, Medicare, Medicaid, and SCHIP Balanced Budget Refinement Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	H.R.3665, Prescription Price Equity Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.3983, Helping to Improve Technology Education and Achievement Act of 2000, Advocate for sufficient visas for medical researchers.
16	Lobbying Issues	H.R.4227, Technology Worker Temporary Relief Act, Advocate for sufficient visas for medical researchers.
16	Lobbying Issues	H.R.4234, Prescription Drug Assistance Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.4607, Medicare Prescription Drug Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.4686, Fair Balance Prescription Drug Advertisement Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.R.547, Taxpayers' Cancer Research Funding Act of 1999, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	H.R.616, Health Care Research and Development and Taxpayer Protection Act, Monitor and advocate positions that will not adversely affect the pharmaceutical industry.
16	Lobbying Issues	H.R.664, Prescription Drug Fairness for Seniors Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.723, Making Affordable Prescriptions Available for Seniors Act, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	H.R.785, Biomedical Research Assistance Voluntary Option Act, Monitor the bill and advocate positions that promote medical research.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.805, Generic Drugs Access Act of 1999, Monitor and advocate positions that will not adversely affect the pharmaceutical industry.
16	Lobbying Issues	H.R.886, Medicare Prescription Drug Coverage Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.RES.435, Expressing the sense of the House of Representatives that Medicare beneficiaries should have access to outpatient prescription drug coverage, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	H.RES.515, Providing for consideration of the bill (H.R. 4577) making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal...
16	Lobbying Issues	S.1091, Pediatric Research Initiative Act of 1999, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	S.118, Consumer Involvement in Breast Cancer Research Act, Monitor the bill and advocate positions that promote medical research.
16	Lobbying Issues	S.1191, International Prescription Drug Parity Act, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.1322, Genetic Nondiscrimination in Health Insurance and Employment Act of 1999, Monitor the effect of the bill on medical research.
16	Lobbying Issues	S.1429, Taxpayer Refund Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.1462, To amend the Federal Food, Drug, and Cosmetic Act to permit importation in personal baggage and through mail order of certain covered products for personal use from Canada, and for... Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.1480, Seniors Prescription Insurance Coverage Equity (SPICE) Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.1535, Medicare Easing Prescription Drugs for Seniors Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.1626, Medicare Patient Access to Technology Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.1788, Medicare, Medicaid, and SCHIP Adjustment Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	S.1795, Drug Gap Insurance Act for Seniors Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.1837, Healthy Seniors Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.1895, Medicare Preservation and Improvement Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.2015, Stem Cell Research Act of 2000, Monitor for the impact on medical research.
16	Lobbying Issues	S.2045, American Competitiveness in the Twenty-first Century Act of 2000, Advocate for sufficient visas for medical researchers.
16	Lobbying Issues	S.2237, Seniors' Security Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.2378, Stop All Frequent Errors (SAFE) in Medicare and Medicaid Act of 2000, Monitor for impact on the industry.
16	Lobbying Issues	S.2464, Prescription Drug Fairness Act, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.2466, To require the United States Trade Representative to enter into negotiations to eliminate price controls imposed by certain foreign countries on prescription drugs, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.2520, Medicine Equity and Drug Safety Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.2753, Medicare Expansion for Needed Drugs (MEND) Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.2758, Medicare Outpatient Drug Act of 2000, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.543, Genetic Information Nondiscrimination in Health Insurance Act of 1999, Monitor the effect of the bill on medical research.

Page

#5

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.573, Medical Information Privacy and Security Act. Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.
16	Lobbying Issues	S.578, Health Care PEN Act. Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.
16	Lobbying Issues	S.696, Medicare Prescription Drug Coverage Act of 1999, Lobbied on Medicare coverage regulations.
16	Lobbying Issues	S.841, Access to Rx Medications in Medicare Act of 1999, Lobbied for pharmaceutical benefits for Medicare beneficiaries.
16	Lobbying Issues	S.881, Medical Information Protection Act of 1999, Advocate positions that protect an individual's right to privacy and the industry's need to access data essential for medical research.
16	Lobbying Issues	Medicare Outpatient Payment Regulations, lobby on regulations governing Medicare reimbursement of hospital outpatients' prescription drugs. Medicare Ostomy Regulations, lobby on coverage and payment for ostomy products. H.R.4778, Medicare Guaranteed and Defined Rx Benefit and Health Care Provider Relief Act of 2008. Lobbied on Medicare coverage regulations. H.R. 4743, Drug Availability and Health Care Access Act. Lobbied on Medicare coverage regulations. H.R.4764, To eliminate price controls imposed by foreign countries on Rx drugs. Lobbied on Medicare coverage regulations. H.R. 4772, Pharmaceutical Products Price Equity Act. Lobbied on Medicare coverage regulations. S.2836, Medicare Rx Drug Discount and Security Act. Lobbied on Medicare coverage regulations.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LAW (one per page)

16. Specific Lobbying issues

**H.R.2326, Human Cloning Research Prohibition Act, Monitor the effect of the bill on the legitimate medical research.**

**H.R.571, Human Cloning Prevention Act of 1999, Monitor the effect of bill on the legitimate medical research.**

**S.353, Class Action Fairness Act of 1999, Support the passage of legislation to ensure fair treatment of class action law suits.**

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
<b>Keaney, David</b>		No
<b>Ryan, John</b>		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 17 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.R. 4577, The Consolidated Appropriations Act for FY 2001, Advocated for changes in Medicare payment rate for oncology and coverage criteria for ostomy products.

H.R.1544, To require the Secretary of Health and Human Services to establish a demonstration project to provide Medicare beneficiaries greater information with respect to various courses of treatment., Monitor bill and advocate positions that protect the patient and the industry's best interests.

H.R.358, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.

H.R.448, Patient Protection Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.

S.1344, Patients' Bill of Rights Plus Act (Public Print), Monitor bill and advocate positions that protect the patient and the industry's best interests.

17. House(s) of Congress and Federal agencies contacted  Check if None

Health Care Finance Administration - HCFA

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Keaney, David		No
Ryan, John		No
Thompson, Richard		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 18 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.1788, Medicare, Medicaid, and SCHIP Adjustment Act of 1999, Lobby to improve patient access to cancer therapies in hospital outpatient departments.
16	Lobbying Issues	S.240, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.2549, National Defense Authorization Act for Fiscal Year 2001, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.300, Patients' Bill of Rights Plus Act, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.326, Patients' Bill of Rights Act, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.374, Promoting Responsible Managed Care Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.6, Patients' Bill of Rights Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	S.751, Seniors Safety Act of 1999, Monitor bill and advocate positions that protect the patient and the industry's best interests.
16	Lobbying Issues	Medicare Outpatient Payment Regulations, lobbying on regulations governing Medicare reimbursement of hospital outpatient prescription drugs. Medicare Ostomy Regulations, lobby on coverage and payment for ostomy products.

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

**H.R.4986, FSC Repeal and Extraterritorial Income Exclusion Act of 2000, Lobbied to obtain passage of legislation to conform with the World Trade Organization's recent rulings.  
R&D Tax Credit, to make permanent the research and development tax credit.**

17. House(s) of Congress and Federal agencies contacted  Check if None  
House of Representatives  
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Carozza, Michael		No
Kesney, David		No
Ryan, John		No
Thompson, Richard		No
Warr, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 20 of 22

Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

H.R.434, African Growth and Opportunity Act, Establishes a U.S. policy of trade and investment with the emerging economies of sub-Saharan Africa.

S.666, African Growth and Opportunity Act, Establishes a U.S. policy of trade and investment with the emerging economies of sub-Saharan Africa.

Canada Patent Issue: Canada's failure to provide 20 year patent term in accordance with GATT/TRIPS.

17. House(s) of Congress and Federal agencies contacted  Check if None

House of Representatives

Senate

The Department of Health and Human Services

The Food and Drug Administration

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Keaney, David		No
Thompson, Richard		No
Warr, David		No

19. Interest of each foreign entity in the specific issues listed on line 16 above  Check if None

Signature \_\_\_\_\_ Date 8/1/2001

Printed Name and Title Richard Thompson - Vice President, Government Affairs Page 21 of 22

Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

**Information Update Page - Complete ONLY where registration information has changed.**

20. Client new address

21. Client new principal place of business (if different from line 20)

City \_\_\_\_\_ State/Zip (or Country) \_\_\_\_\_

22. New general description of client's business or activities

**LOBBYIST UPDATE**

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

**Skrabut, Lucy**

**ISSUE UPDATE**

24. General lobbying issues previously reported that **no longer** pertain

**AFFILIATED ORGANIZATIONS**

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)

26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client


**FOREIGN ENTITIES**

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities	Ownership % in client

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant, client, or affiliated organization

Signature



Date **8/1/2001**

Printed Name and Title

**Richard Thompson - Vice President, Government Affairs**

Page **22** of **22**